Table 3.
Antibody based immunotherapies under investigation (based on www.clinicaltrials.gov at 05/25/2020).
| Antibody constructions | Name | Results | Status | Clinical Trials |
|---|---|---|---|---|
| CD123 | talacotuzumab | Toxicity | Terminated | NCT02472145 |
| CD38 | daratumumab | Under investigations | Phase 1/2 | NCT03537599 |
| Phase 2 | NCT03067571 | |||
| CD44 | H90 | LSC targeting | Pre-clinical | None |
| CD47 | Hu5F9-G4 | Under investigations | Phase 1 | NCT02678338, NCT03248479 |
| CD70 | cusatuzumab | CR/CRi 82% | Phase 1 | NCT04150887, |
| SEA-CD70 | Under investigations | Phase 1 | NCT04227847 | |
| CD157 | MEN1112 | No report | Phase 1 | NCT02353143 |
| FLT3 | ASP1235 | Under investigations | Phase 1 | NCT02864290 |
| ILRAP | mAb81.2, mAb3F8 | LSC targeting | Pre-clinical | None |
| MAB-hR3 | LSC targeting | Pre-clinical | None | |
| CD3/CD33 BiTE | AMG-330 | Under investigations | Phase 1 | NCT02520427 |
| GEM333 | Under investigations | Phase 1 | NCT03516760 | |
| JNJ-67371244 | Under investigations | Phase 1 | NCT03915379 | |
| CD3/CD33 Tandem Diabody | AMV564 | Under investigations | Phase 1 | NCT03144245 |
| CD3/CD33/PD-1 CiTE | AML targeting | Pre-clinical | None | |
| CD3/CD123 DART | MGD006 (flotetuzumab) | Under investigations | Phase 1/2 | NCT02152956, NCT04158739 |
| CD3/CD123 BiTE | XmAb14045 | CR/CRI 23% | Phase 1 | NCT02730312 |
| CD3/CD123 DuoBody | JNJ-63709178 | Under investigations | Phase 1 | NCT02715011 |
| CD3/CCL-1 BiTE | MCLA-117 | Under investigations | Phase 1 | NCT03038230 |
| CD16/CD33 BiKE | 1633 | AML targeting | Pre-clinical | None |
| CD16/IL-15/CD33 TriKE | 161533 (GTB-3550) | Under investigations | Phase 1/2 | NCT03214666 |
| CD16/CD33/CD123 TriKE | SPM-2 | AML & LSC targeting | Pre-clinical | None |
Progress of antibody-based immunotherapy studies in AML. CR, complete response. CRi, complete response with incomplete hematological recovery response. AML, acute myeloid leukemia. LSC, leukemic stem cells. BiTE, Bispecific T-cell Engager. CiTE, Checkpoint inhibitor T-cell Engager. DART, Dual-Affinity Re-Targeting. BiKE, Bispecific Killer Engagers. TriKE, Trispecific Killer Engagers.